PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported its Q1 earnings results on Monday, May 16, 2022 at 06:00 AM.
Here’s what investors need to know about the announcement.
Earnings
PhaseBio Pharmaceuticals beat estimated earnings by 65.15%, reporting an EPS of $-0.23 versus an estimate of $-0.66.
Revenue was up $117.00 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.31 which was followed by a 5.0% drop in the share price the next day.
Here’s a look at PhaseBio Pharmaceuticals’s past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.59 | -0.61 | -0.48 | -0.69 |
| EPS Actual | -0.90 | -0.66 | -0.60 | -0.87 |
| Revenue Estimate | 1.97M | 1.07M | 4.02M | 30.00K |
| Revenue Actual | 158.00K | 335.00K | 10.34M | 0 |
To track all earnings releases for PhaseBio Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.